Jackson Scott Thomas 4

4 · Mural Oncology plc · Filed Dec 5, 2025

Form 4

Period: 2025-12-05

Director

Transactions

Disposition to Issuer
Stock Option (right to buy)
2025-12-05−8,637→ 0 total
Exercise: $2.56Exp: 2035-06-10→ Ordinary Shares (8,637 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-12-05−8,462→ 0 total
Exercise: $3.35Exp: 2034-05-29→ Ordinary Shares (8,462 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-12-05−15,021→ 0 total
Exercise: $3.61Exp: 2033-12-13→ Ordinary Shares (15,021 underlying)

Footnotes (2)

[F1]This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
[F2]Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

Documents

1 file